We recently compiled a list of the top 5 AI-powered biotech stocks to buy right now. If you want to see the full list and want to know how we came up with these stocks, visit Top 10 AI-Powered Biotech Stocks to Buy Right Now.

5. Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Number of Hedge Fund Holders: 39

Kymera Therapeutics, Inc. (NASDAQ:KYMR) is among the best biotech stocks.

TheFly reported on April 13 that KYMR announced that the U.S. Food and Drug Administration granted Fast Track designation to KT-621, its first-in-class oral STAT6 degrader being developed for moderate to severe eosinophilic asthma. The investigational once-daily oral therapy is currently in ongoing Phase 2b clinical studies evaluating its potential in asthma and other Type 2 inflammatory conditions.

Early clinical and preclinical data have shown reductions in key inflammatory biomarkers and improvements in disease control measures, supporting its mechanism of action. The designation is intended to facilitate closer regulatory engagement and may help accelerate development timelines for the program as it advances toward later-stage trials.

Further reinforcing the company’s operational momentum, on April 9, Gilead Sciences exercised its option under a collaboration agreement to obtain exclusive global rights to KT-200, a first-in-class oral CDK2 molecular glue degrader developed by Kymera Therapeutics, Inc. (NASDAQ:KYMR). The decision advances the program toward IND-enabling studies, with a planned IND filing targeted for 2027.

As part of the transaction, KYMR is set to receive a $45 million milestone payment and remains eligible for additional future milestone payments and tiered royalties on potential commercial sales. KT-200 is designed to selectively degrade CDK2, a key driver of tumor growth, offering a differentiated approach for cancers driven by CCNE1 alterations, supported by strong preclinical activity and a favorable safety profile.

Kymera Therapeutics, Inc. (NASDAQ:KYMR) is an AI-driven biotechnology company developing targeted protein degradation therapies for cancer and immune-inflammatory diseases. It uses computational drug discovery to design small-molecule drugs that eliminate disease-causing proteins instead of inhibiting them.

4. IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Number of Hedge Fund Holders: 40

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is among the best biotech stocks to invest in.

TheFly reported on April 14 that Wedbush Securities increased its price target on IDYA from $52 to $58 while maintaining an Outperform rating. The update followed the company’s release of top-line results from its Phase 2/3 OptimUM-02 clinical trial. Management reported that safety outcomes remain consistent with earlier studies, with adverse events generally manageable. The firm also noted that additional detailed findings from the study are expected to be shared at a major medical conference in 2026, which could provide further clarity on the program’s clinical profile and future development potential.

Adding to the company’s operational momentum, on April 6, IDEAYA Biosciences, Inc. (NASDAQ:IDYA) reported that it has begun patient enrollment in a Phase 1 dose-escalation study of IDE574, a first-in-class oral small-molecule therapy designed to inhibit KAT6 and KAT7, two epigenetic targets involved in cancer cell survival.

The early-stage trial will assess safety, pharmacokinetics, and preliminary anti-tumor activity as a monotherapy in patients with advanced solid tumors, including breast, prostate, colorectal, and lung cancers. The program is intended to evaluate a novel dual-mechanism approach aimed at overcoming resistance pathways in oncology and expanding treatment options in multiple high-need cancer indications through epigenetic modulation strategies.

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is an AI-driven precision oncology company focused on synthetic lethality-based cancer therapies. It uses machine learning and physics-based drug discovery to develop first-in-class targeted cancer treatments guided by molecular diagnostics.

3. Caris Life Sciences, Inc. (NASDAQ:CAI)

Number of Hedge Fund Holders: 44

Caris Life Sciences, Inc. (NASDAQ:CAI) is among the best biotech stocks. 

TheFly reported on April 10 that Piper Sandler began coverage of CAI with a Neutral rating and a $21 price target. The firm highlighted the company’s combination of strong scientific capabilities and relatively stable financial profile compared to many peers in the space. It projected revenue growth of around 20% over the next few years but indicated that further acceleration in therapy selection services, potentially driven by Salesforce expansion or new product offerings, would be needed before adopting a more positive stance on the stock.

In a significant operational development, on April 1, Caris Life Sciences, Inc. (NASDAQ:CAI) introduced Caris ChromoSeq, a new genomic testing platform combining whole genome and whole transcriptome sequencing to evaluate myeloid cancers. The assay is designed for conditions such as acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms, as well as cases with persistent unexplained cytopenia.

It enables comprehensive detection of mutations, structural changes, and chromosomal abnormalities through a single test, reducing the need for multiple diagnostic procedures. The platform delivers in-depth genomic data and integrates findings into a unified report, supporting faster and more informed clinical decisions. Results are expected within approximately seven days, improving efficiency in patient care.

Caris Life Sciences, Inc. (NASDAQ:CAI) is an AI-driven precision medicine company that uses large-scale clinico-genomic data and molecular profiling to guide cancer diagnosis and treatment. Its platforms apply machine learning to predict therapy response and improve personalized oncology outcomes.

2. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Number of Hedge Fund Holders: 64

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is among the best biotech stocks to invest in.

TheFly reported on April 7 that RBC Capital Markets slightly increased its price target on VRTX from $541 to $543 while maintaining an Outperform rating. The revision was part of a broader biotech sector preview ahead of first-quarter earnings. The firm noted that near-term performance could face pressure from seasonal factors such as reimbursement resets, fewer selling days, and weather-related disruptions, particularly affecting newer and clinic-based products. However, it also highlighted that renewed merger and acquisition activity and clearer expectations around pricing policies could help stabilize sentiment and support the sector despite ongoing macroeconomic uncertainty.

A major operational milestone was announced by the company on April 1. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced that it received expanded approval from the U.S. Food and Drug Administration for ALYFTREK, widening its use in treating cystic fibrosis for patients aged 6 and older with eligible CFTR gene variants. The update also broadened the indication for TRIKAFTA, extending treatment access to younger patients and additional genetic variants.

The decision was supported by extensive clinical and laboratory evidence across hundreds of CFTR mutations, significantly increasing the number of individuals eligible for therapy. This expansion allows a larger portion of the cystic fibrosis population in the United States to receive treatment targeting the underlying cause of the disease.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a leading biotech company integrating AI and machine learning across drug discovery and development. It uses data-driven platforms to accelerate small molecule, gene-editing, and cell therapy programs for diseases like cystic fibrosis, kidney disease, diabetes, and pain.

1. Insmed Incorporated (NASDAQ:INSM)

Number of Hedge Fund Holders: 75

Insmed Incorporated (NASDAQ:INSM) is one of the best biotech stocks.

TheFly reported on April 16 that Guggenheim Securities increased its price target on INSM from $227 to $230 while maintaining a Buy rating. The adjustment was made within a broader first-quarter earnings preview covering commercial-stage biotechnology companies. The firm updated its financial assumptions across the coverage group as part of its model revisions ahead of upcoming quarterly results.

Separately, earlier on April 14, RBC Capital Markets increased its price target on Insmed Incorporated (NASDAQ:INSM) from $212 to $216 while maintaining an Outperform rating. The update incorporated findings from a physician survey assessing early real-world experience with Brinsupri and expectations for future prescribing behavior. Responses indicated favorable perceptions of the drug’s clinical profile and a willingness among physicians to increase its use over time. The research also suggested that the population of patients considered eligible for treatment may expand significantly, supporting a more optimistic outlook on the product’s longer-term commercial opportunity.

Insmed Incorporated (NASDAQ:INSM) is an AI-enabled biopharmaceutical company focused on rare diseases and gene therapies. It integrates machine learning and Google Cloud AI to accelerate drug discovery, optimize protein engineering, and improve clinical development efficiency for serious respiratory and genetic disorders.

READ NEXT: 10 Best Mid Cap Stocks to Invest In According to Billionaires and 10 Best Cheap Stocks Under $10 to Buy in April.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below